Latest news with #TiborNemes

National Post

Stallergenes Greer Announces Palforzia® Featured on "The Balancing Act" Airing on Lifetime TV

Article content National TV Segment Highlights FDA-Approved Oral Immunotherapy Treatment for Peanut Allergy Article content Segment premiered on Wednesday, July 30 and will be rebroadcast on Thursday, July 31, at 7:30 a.m. PT/ET Article content LENOIR, N.C. — Stallergenes Greer, a global leader in allergy therapeutics, today announced that a new segment of 'The Balancing Act ® ' airing on Lifetime TV featured its product Palforzia ® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first and only U.S. Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for peanut allergy in children ages 1 through 17 years. 1 The Stallergenes Greer sponsored segment premiered nationwide on Wednesday, July 30 at 7:30 a.m. (ET/PT) and features the story of a family with a peanut allergic child who was treated with Palforzia ® . Article content 'We are proud to see Palforzia ® featured on 'The Balancing Act ®,' bringing national visibility to peanut allergy and a first of it's kind, FDA-approved oral immunotherapy treatment option for children and toddlers that can help to reduce the risk of life-threatening reactions that can occur with a peanut allergy,' Article content said Tibor Nemes, Executive Vice President, Head of Americas for Stallergenes Greer Article content . 'This segment is an opportunity to educate patients, caregivers and healthcare providers about Palforzia ®, and to further our commitment as Stallergenes Greer to provide innovative allergen immunotherapy (AIT) treatments to the allergy community that we serve.' Peanut allergy currently affects approximately 2% of the US pediatric population 2-3 Compared to other food allergies, peanut allergy is associated with higher rates of morbidity due to accidental exposure 4. The severity of reactions in some patients despite strict allergen avoidance efforts highlights the need for safe and effective therapies. 5 The featured segment included insights shared by Pediatric Allergist and Immunologist, Panida Sriaroon, M.D., on food allergies and the challenges that some patients with food allergies and their families may face. Dr. Sriaroon, also presented Palforzia ® and its significance as the first and only FDA-approved oral immunotherapy treatment option available in the treatment landscape for peanut allergy. Article content Palforzia ® was first approved by the FDA in 2020, under Aimmune Therapeutics, Inc., as an oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut in children ages 4 through 17 years. In 2024, the FDA approved Palforzia ® for the expanded indication for toddler patients (ages 1 through 3 years) and the toddler product was launched in March 2025 by Stallergenes Greer. Article content In addition to the July 30 premiere, the featured segment on 'The Balancing Act' will be rebroadcast on Thursday, July 31, at 7:30 a.m. (ET/PT). It can also be viewed on the show's website Palforzia ® is only available through a REMS (Risk Evaluation and Mitigation Strategy) program. Additional information about Palforzia ®, including Boxed Warning, full Prescribing Information and Medication Guide is available at *The participants featured in this segment were compensated for their time. Article content ABOUT PALFORZIA ® Article content Palforzia ® is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. Palforzia ® is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 1 to 17 years. Up-Dosing and Maintenance may be continued in patients 1 year of age and older. Article content Palforzia ® is to be used in conjunction with a peanut-avoidant diet. Article content Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis. Article content Palforzia ® is approved by the U.S. Food and Drug Administration (FDA) for ages 1 through 17 years. Article content WARNING: ANAPHYLAXIS: Palforzia ® can cause anaphylaxis, which may be life-threatening and can occur at any time during Palforzia ® therapy. Prescribe epinephrine, instruct and treat patients on its appropriate use, and instruct patients to see immediate medical care upon its use. Do not administer Palforzia ® to patients with uncontrolled asthma. Dose modifications may be necessary following a anaphylactic reaction. Observe patients during and after administration of the Initial Dose Escalation and the first dose of each Up-Dose level, for at least 60 minutes. Palforzia ® is available only through a restricted program called the Palforzia ® REMS. Article content is contraindicated in patients with uncontrolled asthma, or with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal diseases. Article content WARNINGS AND PRECAUTIONS: Anaphylaxis: Article content Palforzia Article content ® Article content can cause anaphylaxis, which may be life-threatening. Palforzia Article content ® Article content is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palforzia Article content ® Article content REMS because of the risk of anaphylaxis. Only prescribers, healthcare settings, pharmacies, and patients certified and enrolled in the REMS Program can prescribe, receive, dispense or administer Palforzia Article content ® Article content ® Article content dosing, including Maintenance and in subjects who have undergone recommended Up-Dosing and dose modification procedures. Do not initiate Palforzia Article content ® Article content treatment in a patient who has had severe or life-threatening anaphylaxis within the previous 60 days. Palforzia Article content ® Article content may not be suitable for patients with certain medical conditions that may reduce the ability to survive anaphylaxis, including, but not limited to, markedly compromised lung function, severe mast cell disorder, or cardiovascular disease. In addition, Palforzia Article content ® Article content may not be suitable for patients taking medications that can inhibit or potentiate the effects of epinephrine. All Initial Dose Escalation doses and the first dose of each Up-Dosing level must be administered under observation in a certified healthcare setting. Patients may be more likely to experience allergic reactions following Palforzia Article content ® Article content administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (e.g., viral infection), or fasting. Other potential cofactors may include menstruation, sleep deprivation, nonsteroidal anti-inflammatory drug use, or uncontrolled asthma. Patients should be proactively counseled about the potential for the increased risk of anaphylaxis in the presence of these cofactors. If possible, adjust the time of dosing to avoid these cofactors. If it is not possible to avoid these cofactors, consider withholding Palforzia Article content ® Article content temporarily. Article content Asthma: Article content ® Article content . Palforzia Article content ® Article content should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of Palforzia Article content ® Article content ® Article content . Article content Eosinophilic Gastrointestinal Disease: Article content Discontinue Palforzia Article content ® Article content and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastrointestinal symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain. Article content Gastrointestinal Adverse Reactions: Article content ® Article content -treated subjects, and dose modification should be considered for patients who report these reactions. For severe or persistent gastrointestinal symptoms, consider a diagnosis of eosinophilic esophagitis. Article content ® Article content Article content (incidence ≥5%) are cough, sneezing, rhinitis, nasal congestion, throat irritation, wheezing, abdominal pain, vomiting, diarrhea, oral pruritus, oropharyngeal pain, urticaria, rash, pruritus, and perioral dermatitis. The most common adverse reactions reported in subjects ages 4 through 17 years treated with Palforzia Article content ® Article content (incidence ≥5% and at least 5% greater than placebo) are abdominal pain, vomiting, nausea, oral pruritus, oral paresthesia, throat irritation, cough, rhinorrhea, sneezing, throat tightness, wheezing, dyspnea, urticaria, anaphylactic reaction, and ear pruritus. Article content ABOUT THE BALANCING ACT Article content The Balancing Act ® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime ® and find all previously aired episodes on ABOUT STALLERGENES GREER Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. Article content PALFORZIA [package insert]. Lenoir, NC; Greer Laboratories, Inc. Article content 2 Article content Bilaver LA, Chadha AS, Doshi P, O'Dwyer L, Gupta RS. Economic burden of food allergy: A systematic review. Ann Allergy Asthma Immunol 2019;122:373–80 e1. Article content 3 Article content Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011;128:e9–17. Article content 4 Article content The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: Article content . Accessed August 31, 2023 Article content Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023. Article content Article content Article content Article content Article content Contacts Article content Stallergenes Greer USA Article content Article content Article content